Temozolomide
The only chemotherapy proven to extend life in glioblastoma, given during and after radiation. It works best when the tumour has switched off a repair gene called MGMT.
Overview
Stupp/EORTC 26981-NCIC (2005): adding concurrent and adjuvant temozolomide to radiotherapy raised median OS from 12.1 to 14.6 months and 2-year survival from 10% to 27%. Benefit concentrates in MGMT-promoter-methylated tumours (median OS ~23 months vs ~13 months unmethylated). Also standard with radiotherapy in grade 3 astrocytoma (CATNON) and, with PCV as an alternative, in oligodendroglioma. Oral, well tolerated; lymphopenia and hypermutation at recurrence are the costs.
1.Temozolomide slips into a pocket on its target.
Compare all products across the US, EU, UK, Japan, China and Australia →
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 1999 | Refractory anaplastic astrocytoma |
| US | 2005 | Newly diagnosed glioblastoma with radiotherapy |
| EU | 1999 | Temodal; malignant glioma (recurrent 1999; newly diagnosed glioblastoma with radiotherapy 2005); 26 Jan 1999 |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"Temozolomide" OR ABSTRACT:"Temozolomide" OR TITLE:"Temodar" OR ABSTRACT:"Temodar") AND (radiopharmaceutical OR radioligand OR radionuclide OR theranostic OR "nuclear medicine" OR "molecular imaging" OR radiotracer OR scintigraphy OR cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Temozolomide, not a curated reading list.
Similar pages
not linked directly; found by shared links- AgentCapecitabine
Shares PRRT (177Lu-DOTATATE) with capecitabine and temozolomide (CAPTEM), Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE.
- IndicationHereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)
Shares SDH deficiency (SDHB immunohistochemistry loss), Metastatic pheochromocytoma and paraganglioma, Pheochromocytoma and paraganglioma (PPGL).
- AgentSunitinib
Shares SDH deficiency (SDHB immunohistochemistry loss), Metastatic pheochromocytoma and paraganglioma, Pheochromocytoma and paraganglioma (PPGL).
- AgentFluorodopa F-18
Shares Glioma & glioblastoma, Metastatic pheochromocytoma and paraganglioma, Pheochromocytoma and paraganglioma (PPGL).
- TargetNorepinephrine transporter (NET)
Shares High-risk neuroblastoma, Metastatic pheochromocytoma and paraganglioma, Pheochromocytoma and paraganglioma (PPGL).
- Agent131I-MIBG (iobenguane I-131) therapy
Shares High-risk neuroblastoma, Metastatic pheochromocytoma and paraganglioma, Pheochromocytoma and paraganglioma (PPGL).
- TechnologyMIBG imaging and 131I-MIBG therapy
Shares High-risk neuroblastoma, Metastatic pheochromocytoma and paraganglioma, Pheochromocytoma and paraganglioma (PPGL).
- AgentIobenguane I-123
Shares Metastatic pheochromocytoma and paraganglioma, Pheochromocytoma and paraganglioma (PPGL).